Previous Close | 1.7900 |
Open | 1.7300 |
Bid | 1.8100 x 1000 |
Ask | 1.8200 x 800 |
Day's Range | 1.7300 - 1.8150 |
52 Week Range | 1.4300 - 2.9100 |
Volume | |
Avg. Volume | 20,070 |
Market Cap | 26.012M |
Beta (5Y Monthly) | 0.30 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1200 |
Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for CPIX
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2023.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the publication of positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor® in newborn infants, published in the journal Pediatric Drugs1. Caldolor (ibuprofen) injection, is an intravenous non-steroidal anti-inflammatory drug (NSAID) approved by the FDA for the treatment of pain and fever in adults and children. The results of this published study supported